

PRESS RELEASE
10 August 2022 11:00:00 CEST



NEW CoreTherm® study published

In Scandinavian Journal of Urology, a new scientific study was published yesterday on CoreTherm®, ProstaLund's treatment method for benign prostatic hyperplasia. Researchers at The Sahlgrenska Academy in Gothenburg present their study entitled: "Treatment with CoreTherm in 570 patients with prostate volumes of 80-366 ml: an evaluation of short- and long-term retreatment risk"

The aim of this study, with Dr Fredrik Stenmark as lead author, was to evaluate the short- and long-term retreatment risk in men with a large prostates and benign prostate obstruction (BPO) or chronic urinary retention, all primarily treated with CoreTherm.

570 men with prostate volumes ≥ 80 ml treated with CoreTherm 1999–2015 were included in the study and have been followed until December 2019. Only 12% needed further surgical treatment during the follow-up period which averaged 11 years but up to 20 years. The long-term re-treatment rate in the study was 23% where the majority of these could be retreated with CoreTherm or TURP and for only 3% open surgery was necessary to resort to.

The authors conclude that CoreTherm is a suitable outpatient treatment option in patients with profoundly enlarged prostates, regardless of age, prostate size, and reason for treatment.

CEO Johan Wennerholm comments: "It is both important and gratifying that the academy continues to study our method. For men with very large prostate glands (larger than 80 ml), open surgical procedures are often offered as the size of the gland makes them unsuitable for a TUR-P. This means that the operations are performed under general anesthesia, with sometimes a high risk of bleeding and other complications, in addition to a in many cases time-consuming and expensive operation. We now have scientific evidence that CoreTherm is a safe and highly effective treatment option, both in the short and long term, for this patient group."

<https://doi.org/10.1080/21681805.2022.2108139>

For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com



PRESS RELEASE
10 August 2022 11:00:00 CEST

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

Attachments

NEW CoreTherm® study published